ArticleExperimental and therapeutic medicine2013
Anti-interleukin-6 receptor antibody reduces neuropathic pain following spinal cord injury in mice.
Article in Experimental and therapeutic medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 55 citations in OpenAlex.
- Higher Circulating IL-6 levels as a predictor for poor outcome after migraine preventive treatment: a prospective study.The journal of headache and pain · 2025Trial
- Translational evidence for increased central amygdala IL-6 activity in alcohol dependence.Journal of neuroinflammation · 2026Article
- Interleukin-6 as a keystone cytokine in experimental rat models of chemotherapy-induced peripheral neurotoxicity.Scientific reports · 2026Article
- Targeting IL-6 as a novel therapeutic approach for alcohol abstinence - related mechanical allodynia.Neuropharmacology · 2025Article
- Early Changes in Respiration and Motor Activity after Spinal Cord Injury Predict Pain-Related Outcomes in Mice.bioRxiv : the preprint server for biology · 2025Article
- Inhibition of the RNA Regulator HuR Mitigates Spinal Cord Injury by Potently Suppressing Post-Injury Neuroinflammation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Pulsed radiofrequency alleviates neuropathic pain by upregulating MG53 to inhibit microglial activation.European journal of medical research · 2024Article
- CCL2 Knockdown Attenuates Inflammatory Response After Spinal Cord Injury Through the PI3K/Akt Signaling Pathway: Bioinformatics Analysis and Experimental Validation.Molecular neurobiology · 2024Article
- Current Concepts of Biomaterial Scaffolds and Regenerative Therapy for Spinal Cord Injury.International journal of molecular sciences · 2023Review
- Regulation of neuropathic pain by microglial Orai1 channels.Science advances · 2023Article
- Resveratrol suppresses neuroinflammation to alleviate mechanical allodynia by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway in a rat model of spinal cord injury.Frontiers in molecular neuroscience · 2023Article
- Integrating the Gut Microbiome and Stress-Diathesis to Explore Post-Trauma Recovery: An Updated Model.Pathogens (Basel, Switzerland) · 2022Article
- Improvements in Intractable Lumbar and LowerExtremity Symptoms after Systemic Administration of Tocilizumab, an Anti-interleukin-6 Receptor Antibody.Asian spine journal · 2022Article
- Spinal Cord Injury Increases Pro-inflammatory Cytokine Expression in Kidney at Acute and Sub-chronic Stages.Inflammation · 2021Article
- Three-dimensional analysis of the characteristics of joint motion and gait pattern in a rodent model following spinal nerve ligation.Biomedical engineering online · 2021Article
- Pain: A Review of Interleukin-6 and Its Roles in the Pain of Rheumatoid Arthritis.Open access rheumatology : research and reviews · 2021Review
- Regulation of T-type CaJournal of neurochemistry · 2019Article
- Pifithrin-μ modulates microglial activation and promotes histological recovery following spinal cord injury.CNS neuroscience & therapeutics · 2019Article
- Transcriptome profiling of dorsal root ganglia in a rat model of complex regional pain syndrome type-I reveals potential mechanisms involved in pain.Journal of pain research · 2019Article
- Anti-IL-6 Receptor Antibody Inhibits Spontaneous Pain at the Pre-onset of Experimental Autoimmune Encephalomyelitis in Mice.Frontiers in neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study reports the beneficial effects of an anti-mouse interleukin-6 (IL-6) receptor antibody (MR16-1) on neuropathic pain in mice with spinal cord injury (SCI). Following laminectomy, contusion SCI models were produced using an Infinite Horizon (IH)-impactor. MR16-1 was continuously injected for 14 days using Alzet osmotic pumps. A mouse IL-6 ELISA kit was then used to analyze IL-6 levels in the spinal cord tissue between 12 and 72 h after injury. Motor and sensory functions were evaluated each week using the Basso Mouse Scale (BMS), plantar von Frey and thermal threshold tests. Histological examinations were performed 42 days after SCI. Between 24 and 72 h after SCI, the expression levels of IL-6 were significantly decreased in the MR16-1 treated group. Six weeks after surgery, the BMS score of the MR16-1-treated group indicated significant recovery of neurological functions. MR16-1-treated mice in the SCI group exhibited lower paw withdrawal thresholds in the plantar von Frey and thermal tests, which were used to evaluate allodynia. MR16-1 treatment significantly increased the area of Luxol fast blue-stained tissue, representing spared myelin sheaths. These results indicate that the continuous inhibition of IL-6 signaling by MR16-1 between the early and sub-acute phases following SCI leads to neurological recovery and the suppression of hyperalgesia and allodynia. Overall, our data suggest that the inhibition of severe inflammation may be a promising neuroprotective approach to limit secondary injury following SCI and that an anti-IL-6 receptor antibody may have clinical potential for the treatment of SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.